Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
Neuro Central
by
6h ago
The Application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CheckMate--Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who have not received prior syst ..read more
Visit website
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
Neuro Central
by
1d ago
-- Continued Improvements in RSBQ and CGI-I scores seen with long-term DAYBUE treatment in Phase 3 LAVENDER™ and LILAC studies -- DAYBUE safety profile was consistent with findings from the LAVENDER trial SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from two open-label extension studies, LILAC-1™ and LILAC-2™, which showed that patients treated with DAYBUE™ who completed these studies experienced improvement in Rett symptoms as measured by the Rett Syndrome Behaviour Questionnaire (RSBQ). LILAC-1 was a 40-week, o ..read more
Visit website
Dxcover Ltd Joins in Recognizing July 17 2024 as #GBMDay in the US
Neuro Central
by
2d ago
Company establishing US operations in Nashville TN GLASGOW, Scotland & NASHVILLE, Tenn.--(BUSINESS WIRE)--#Dxcover--Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA-Dx) for early detection of solid tumor cancers, joins in recognizing July 17, 2024 as “Glioblastoma Awareness Day” in the US. The 118th Congress recently passed a bi-partisan resolution calling for greater public awareness of glioblastoma, honors those who have been impacted by the disease and supports efforts which improve the long-term prognosis for and quality of life f ..read more
Visit website
Biomarkers of progressive supranuclear palsy identified in spinal fluid
Neuro Central
by Annie Coulson
3d ago
The recent discovery of a unique protein pattern in spinal fluid may make earlier diagnosis of progressive supranuclear palsy a reality. Researchers at the University of California San Francisco (CA, USA) have identified a pattern of proteins in cerebral spinal fluid that is indicative of progressive supranuclear palsy (PSP), a neurological disorder that usually goes undiagnosed until after an individual dies. Discovering the fluid biomarkers of PSP is the first step in not only earlier diagnosis but also in developing targeted therapeutics for the elusive neurological condition. [u ..read more
Visit website
TME Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024
Neuro Central
by
3d ago
BERLIN--(BUSINESS WIRE)--TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an abstract featuring results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation at the European Society for Medical Oncology (ESMO) Congress taking place in Barcelona, Spain, September 13-17, 2024. The oral presentation will provide further analysis of the dual inhibition of NOX-A12 and ..read more
Visit website
Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C
Neuro Central
by
3d ago
Study designed to support safety profile showed nizubaglustat was safe and well tolerated Results support continued development of nizubaglustat for GM2 gangliosidosis and Niemann-Pick disease type C with Phase 3 trial[s] planned for 2025 Data to be presented at the SSIEM Annual Symposium 2024 to be held 3-6 September in Porto, Portugal LEIDEN, Netherlands--(BUSINESS WIRE)--#Azafaros--Azafaros B.V. today announced positive topline data from its RAINBOW study, a Phase 2 clinical trial investigating nizubaglustat in patients with a genetic diagnosis of either GM2 gangliosidosis or Niemann-Pic ..read more
Visit website
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
Neuro Central
by
3d ago
– 300 patients enrolled in the study, including patients with and without the cognitive biomarker – – On track to report topline data in October 2024 – – Alto to host investor day focused on ALTO-100 on September 9, 2024 – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of enrollment in its Phase 2b study of ALTO-100 in adults with major depressive disorder (MDD). Topline results from this study ..read more
Visit website
Perry J. Sternberg Joins Sydnexis as Chief Executive Officer
Neuro Central
by
3d ago
Accomplished Industry Leader Brings Extensive Commercialization and Ophthalmic Expertise DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company focused on the treatment of progression of pediatric myopia, is excited to announce the appointment of Perry J. Sternberg as Chief Executive Officer and as a member of the Board of Directors. An accomplished pharma/biotech executive with over 30 years in the industry and 15 years in eye care, Perry will provide invaluable leadership experience to help guide Sydnexis’ strategic direction an ..read more
Visit website
The importance of a patient-centered approach for treatment-resistant depression
Neuro Central
by Annie Coulson
3d ago
Lisa Harding (left) is a psychiatrist with expertise in depression and treatment-resistant depression (TRD). Lisa started her career as an emergency room physician, which helped her grasp what suffering is, benefiting her as a psychiatrist. She was the Chief Resident of Intervention Psychiatry at Yale University (CT, USA), and is an Assistant Clinical Professor in the Department of Psychiatry at Yale. She has a private practice, which accepts Medicare and Medicaid, and has done over 4000 procedures in electroconvulsive shock therapy, transcranial magnetic stimulation, intravenous ketamine and ..read more
Visit website
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Milestone Achievement to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
Neuro Central
by
3d ago
SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced today the attainment of the first milestone in a strategic partnership to advance the development of biomarkers for Alzheimer’s disease (AD) and other neurodegenerative conditions. This milestone marks a key achievement which provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study, POLARIS-AD. POLARIS-AD will enroll up to 1150 participants with early Alzhe ..read more
Visit website

Follow Neuro Central on FeedSpot

Continue with Google
Continue with Apple
OR